Dutasteride reduces prostate cancer risk

Kuritzky, Louis
May 2010
Internal Medicine Alert;5/17/2010, p71
The article focuses on the study which examines the efficacy of dutasteride and finasteride drugs to treat patients with prostate cancer.


Related Articles

  • Finasteride does not reduce PSA's role in prostate cancer detection. Bankhead, Charles // Urology Times;Oct98, Vol. 26 Issue 10, p1 

    Deals with the findings of the Proscar Long-Term Efficacy and Safety Study that treatment of BPH with finasteride does not reduce the effectiveness of PSA testing for prostate cancer. Details on the study; PSA levels reduced by finasterides; Comments on the findings of the study.

  • Finasteride may inhibit PCa progression, invasion. Wirschubsky, Zvi // Urology Times;Jun99, Vol. 27 Issue 6, p14 

    Focuses on the results of research on the effectiveness of finasteride in the prevention of prostate cancer progression and invasion. Cell proliferation and protease production inhibited by finasteride; Inhibition observed in all primary prostate cancer cultures tested.

  • Experts show wide range of opinion on PCa prevention trial.  // Urology Times;Aug2003, Vol. 31 Issue 8, p1 

    Reports on the percentage reduction of prostate cancer incidence in men treated with finasteride in the U.S. Details on the era in prostate cancer prevention; Application of findings by urologists to clinical practice; Development of prostate cancer. INSET: Oral chemotherapy promising for PCa.

  • STUDY: FINASTERIDE WON'T LOWER MEN'S QUALITY OF LIFE.  // Cleveland Clinic Men's Health Advisor;Dec2012, Vol. 14 Issue 12, p2 

    The article offers information on the study which shows that finasteride would not lower the quality of life of men and would not prevent prostate cancer.

  • Cost effectiveness of finasteride: a risky business?  // PharmacoEconomics & Outcomes News;7/10/2010, Issue 607, p6 

    The article discusses the cost effectiveness of finasteride chemoprevention for treating prostate cancer, referencing a study by S. Reed and colleagues presented at the 105th Annual Meeting of the American Urological Association.

  • Gleason grade after hormonal therapy may be invalid. Sieve, Vonne // Urology Times;Apr2004, Vol. 32 Issue 6, p18 

    Discusses findings of the Prostate Cancer Prevention Trial which showed that the use of finasteride or Proscar reduced the biopsy prevalence of prostate cancer compared with placebo. Percentage of cancer reduction in patients receiving the drug; Effects of Gleason grading performed after...

  • Abstracts.  // Geriatrics;Sep2003, Vol. 58 Issue 9, p44 

    Presents abstracts of research in geriatric care. Effect of mentally-demanding activities on decreasing the risk of dementia; Use of finasteride to reduce the risk of prostate cancer; Risk of death and vascular incidence among patients with rheumatoid arthritis.

  • Prostate-Cancer Prevention-with Risks. S. S. // Time International (South Pacific Edition);7/14/2003, Issue 27, p67 

    The article informs about a study by the U.S. National Cancer Institute on the effectiveness of finasteride in treatment of prostate cancer. But in the seven-year study, involving more than 9,000 men ages 55 and older, the finasteride group also had a slightly higher rate of aggressive, high...

  • FDA issues Multiple Drug Warnings.  // OB/GYN Clinical Alert;Aug2011 Pharmacology, p1 

    The article reports on multiple drug safety warnings issued by the U.S. Food and Drug Administration (FDA). It states that the agency is advising physicians to avoid high dose simvastatin (Zocor) because of the risk of myopathy and rhabdomyolysis. Moreover, the agency has issued alert regarding...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics